• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

《国王结节病问卷的开发与验证:用于评估健康状况》。

The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status.

机构信息

Division of Asthma, Allergy and Lung Biology, King's College London, London, UK.

出版信息

Thorax. 2013 Jan;68(1):57-65. doi: 10.1136/thoraxjnl-2012-201962. Epub 2012 Oct 12.

DOI:10.1136/thoraxjnl-2012-201962
PMID:23065052
Abstract

RATIONALE

Health status is impaired in patients with sarcoidosis. There is a paucity of tools that assess health status in sarcoidosis. The objective of this study was to develop and validate the King's Sarcoidosis Questionnaire (KSQ), a new modular health status measure.

METHODS

Patients with sarcoidosis were recruited from outpatient clinics. The development of the questionnaire consisted of three phases: item generation; item reduction, Rasch analysis to create unidimensional scales and validation; repeatability testing.

RESULTS

207 patients with sarcoidosis (organ involvement: 184 lung, 54 skin, 45 eye disease) completed a 65-item preliminary questionnaire. 36 items were removed due to redundancy or poor fit to the Rasch model. The final version of the KSQ consisted of five modules (General health status, Lung, Skin, Eye, Medications). Internal consistency assessed with Cronbach's α coefficient was 0.70-0.93 for KSQ modules. Concurrent validity of the Lung module was high compared with St George's Respiratory Questionnaire (r=-0.83) and moderate when compared to forced vital capacity (r=0.49). Concurrent validity with skin-specific and eye-specific measures ranged from r=-0.4 to 0.8. The KSQ was repeatable over 2 weeks (n=39), intraclass correlation coefficients for modules were 0.90-0.96.

CONCLUSIONS

The KSQ is a brief, valid, self-completed health status measure for sarcoidosis. It can be used in the clinic to assess sarcoidosis from the patients' perspective.

摘要

原理

结节病患者的健康状况受损。目前评估结节病患者健康状况的工具很少。本研究的目的是开发和验证 King's Sarcoidosis Questionnaire(KSQ),这是一种新的模块化健康状况衡量工具。

方法

从门诊诊所招募结节病患者。问卷的开发包括三个阶段:项目生成;项目减少,Rasch 分析创建单一维度量表和验证;重复性测试。

结果

207 名结节病患者(器官受累:184 例肺部,54 例皮肤,45 例眼病)完成了一份 65 项初步问卷。由于冗余或与 Rasch 模型拟合不佳,有 36 个项目被删除。KSQ 的最终版本由五个模块组成(一般健康状况、肺部、皮肤、眼部、药物)。KSQ 模块的内部一致性用 Cronbach's α 系数评估为 0.70-0.93。肺部模块的同时效度与圣乔治呼吸问卷(r=-0.83)高度相关,与用力肺活量(r=0.49)中度相关。与皮肤特异性和眼部特异性测量的同时效度范围从 r=-0.4 到 0.8。KSQ 在 2 周内具有可重复性(n=39),模块的组内相关系数为 0.90-0.96。

结论

KSQ 是一种简短、有效、自我完成的结节病健康状况衡量工具。它可以在诊所中用于从患者的角度评估结节病。

相似文献

1
The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status.《国王结节病问卷的开发与验证:用于评估健康状况》。
Thorax. 2013 Jan;68(1):57-65. doi: 10.1136/thoraxjnl-2012-201962. Epub 2012 Oct 12.
2
The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire.《国王简短间质性肺病(K-BILD)健康状况问卷的制定与验证》。
Thorax. 2012 Sep;67(9):804-10. doi: 10.1136/thoraxjnl-2012-201581. Epub 2012 May 3.
3
Validation of the King's Sarcoidosis Questionnaire (KSQ) in a Dutch sarcoidosis population.国王结节病问卷(KSQ)在荷兰结节病患者群体中的验证。
Sarcoidosis Vasc Diffuse Lung Dis. 2016 Mar 29;33(1):75-82.
4
Translation and psychometric properties of the King's Sarcoidosis Questionnaire (KSQ) in German language.德语版 King's 结节病问卷(KSQ)的翻译及心理测量特性。
Health Qual Life Outcomes. 2019 Apr 11;17(1):62. doi: 10.1186/s12955-019-1131-z.
5
The development and validation of the Bronchiectasis Health Questionnaire.支气管扩张症健康问卷的制定与验证。
Eur Respir J. 2017 May 11;49(5). doi: 10.1183/13993003.01532-2016. Print 2017 May.
6
King's Sarcoidosis Questionnaire (KSQ) - Validation study in Serbian speaking population of sarcoidosis patients.金氏结节病问卷(KSQ)- 塞尔维亚语结节病患者人群的验证研究。
PLoS One. 2023 Sep 5;18(9):e0273126. doi: 10.1371/journal.pone.0273126. eCollection 2023.
7
FeV1 and BMI influence King's Sarcoidosis Questionnaire score in sarcoidosis patients.FEV1 和 BMI 影响结节病患者 King 结节病问卷评分。
BMC Pulm Med. 2021 Dec 3;21(1):395. doi: 10.1186/s12890-021-01761-7.
8
Evaluating the Minimal Clinically Important Difference of the King's Sarcoidosis Questionnaire in a Multicenter Prospective Study.在一项多中心前瞻性研究中评估国王结节病问卷的最小临床重要差异。
Ann Am Thorac Soc. 2021 Mar;18(3):477-485. doi: 10.1513/AnnalsATS.202006-607OC.
9
Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ).一种针对慢性咳嗽患者的症状特异性健康状况测量工具的开发:莱斯特咳嗽问卷(LCQ)。
Thorax. 2003 Apr;58(4):339-43. doi: 10.1136/thorax.58.4.339.
10
Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch.将 King's 简短间质性肺病问卷(K-BILD)翻译成法语、意大利语、瑞典语和荷兰语,并进行验证。
Chron Respir Dis. 2017 May;14(2):140-150. doi: 10.1177/1479972316674425. Epub 2016 Dec 26.

引用本文的文献

1
Phenotypes and Endotypes in Sarcoidosis: Unraveling Prognosis and Disease Course.结节病的表型和内型:解读预后和疾病进程。
Biomedicines. 2025 Jan 24;13(2):287. doi: 10.3390/biomedicines13020287.
2
Health-related quality of life in sarcoidosis patients and the effect of occupational exposures: a cross-sectional study.结节病患者的健康相关生活质量及职业暴露的影响:一项横断面研究。
BMC Pulm Med. 2025 Feb 17;25(1):83. doi: 10.1186/s12890-025-03552-w.
3
Longitudinal validation of King's Sarcoidosis Questionnaire in a prospective cohort with mild sarcoidosis.
在轻度结节病前瞻性队列中对金斯结节病问卷进行纵向验证。
ERJ Open Res. 2024 Nov 11;10(6). doi: 10.1183/23120541.00160-2024. eCollection 2024 Nov.
4
[Position paper of the Austrian Society for Rheumatology and the Austrian Society for Pneumology on the diagnosis and treatment of sarcoidosis 2024].[奥地利风湿病学会和奥地利肺病学会关于结节病诊断与治疗的立场文件(2024年)]
Wien Klin Wochenschr. 2024 Oct;136(Suppl 17):669-687. doi: 10.1007/s00508-024-02444-z. Epub 2024 Oct 9.
5
Ocular sarcoidosis, to screen or not to screen?眼部结节病,筛查还是不筛查?
Front Med (Lausanne). 2024 Feb 19;11:1348435. doi: 10.3389/fmed.2024.1348435. eCollection 2024.
6
Cost-Effectiveness of Acthar Gel versus Standard of Care for the Treatment of Advanced Symptomatic Sarcoidosis.Acthar凝胶与标准治疗方案治疗晚期症状性结节病的成本效益
Clinicoecon Outcomes Res. 2023 Oct 17;15:739-752. doi: 10.2147/CEOR.S428466. eCollection 2023.
7
Test-retest repeatability for Fatigue Assessment Scale, Short-Form 6-Dimension and King's Sarcoidosis Questionnaire in people with sarcoidosis associated fatigue.结节病相关疲劳患者中疲劳评估量表简版6维度及金斯结节病问卷的重测信度
Sarcoidosis Vasc Diffuse Lung Dis. 2023 Sep 13;40(3):e2023041. doi: 10.36141/svdld.v40i3.13253.
8
King's Sarcoidosis Questionnaire (KSQ) - Validation study in Serbian speaking population of sarcoidosis patients.金氏结节病问卷(KSQ)- 塞尔维亚语结节病患者人群的验证研究。
PLoS One. 2023 Sep 5;18(9):e0273126. doi: 10.1371/journal.pone.0273126. eCollection 2023.
9
Validation of the Turkish Version of the Sarcoidosis Health Questionnaire: A cross-sectional study.结节病健康问卷土耳其语版本的验证:一项横断面研究。
Sarcoidosis Vasc Diffuse Lung Dis. 2023 Mar 28;40(1):e2023002. doi: 10.36141/svdld.v40i1.13617.
10
Identifying a core outcome set for pulmonary sarcoidosis research - the Foundation for Sarcoidosis Research - Sarcoidosis Clinical OUtcomes Taskforce (SCOUT).确定结节病肺部研究的核心结局指标集——结节病研究基金会——结节病临床结局特别工作组(SCOUT)。
Sarcoidosis Vasc Diffuse Lung Dis. 2022;39(3):e2022030. doi: 10.36141/svdld.v39i3.12319. Epub 2022 Sep 23.